.Pharmacolibrary.Drugs.ATC.A.A10BB12

Information

Glimepiride is a second-generation sulfonylurea antidiabetic drug used for the treatment of type 2 diabetes mellitus. It stimulates pancreatic beta cells to release insulin, thereby lowering blood glucose levels. Glimepiride is approved and widely used in clinical practice today.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), oral administration, single 2 mg dose.

References

1. Cho, HJ, et al., & Kim, HG (2011). Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population. Clinica chimica acta; international journal of clinical chemistry 412(19-20) 1831–1834. DOI:10.1016/j.cca.2011.06.014 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21704609

2. Lee, HW, et al., & Yoon, YR (2012). Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics. Journal of clinical pharmacy and therapeutics 37(1) 105–111. DOI:10.1111/j.1365-2710.2010.01238.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21208246

3. Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821

Revisions

• 06/2025 initial generated model